Advancing Novel Immunotherapy Approaches for Osteosarcoma and Beyond with Paul Romness, CEO of OS Therapies

In this episode, Ayesha spoke with Paul Romness, MHP, chair and CEO of OS Therapies, a company developing novel immunotherapies for cancers like osteosarcoma and other solid tumors.

Paul shares insights into OS Therapies’ lead program, the scientific rationale behind the company’s innovative immunotherapy approach and how the company is addressing unmet needs in osteosarcoma.

Paul has over 25 years of experience in the biopharmaceutical industry, having served in various functions within major companies like Johnson & Johnson, Amgen and Boehringer Ingelheim.

He has been directly involved in the launch of nine major products in the industry covering indications from oncology to surgery, HIV, COPD and diabetes.

Throughout his professional career and within his community, Paul has focused on and advocated for unmet medical need and getting treatments to patients.

Paul has a Bachelor of Science (BSc) in finance from American University and a Masters of Health Policy (MHP) from George Washington University Medical Center.

Tune in to learn how OS Therapies is advancing immunotherapies for osteosarcoma and other solid tumors through innovative, precision-driven approaches.

For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/

Follow Us on Social Media

Twitter: https://twitter.com/Xtalks
Instagram: https://www.instagram.com/xtalks/
Facebook: https://www.facebook.com/Xtalks.Webinars/
LinkedIn: https://www.linkedin.com/company/xtalks-webconferences
YouTube: https://www.youtube.com/c/XtalksWebinars/featured